Vericel Corporation (VCEL) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 2.05B USD. 52-week range 28.95 to 49.32 USD. Trailing P/E 85.2. Data as of 2026-10-09.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, ...